TapewireFind a company

person · Reporting owner

Kalif Eliyahu Sharon

Disclosed activity across 1 company

Tapewire entity
37892
SEC CIK
0001798443

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063EVP, Chief Financial OfficerJune 11, 2026June 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date June 11, 2026 · Filed June 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect65,621 Reported balance After 2026-06-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-11 · Sale · Disposed 106,563 · Balance 65,621

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.985 to $34.25, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.985 to $34.25, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 11, 2026 Filed Jun 16, 2026 12:28 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 106,563 $34.10 $3,633,308.11
Disclosure

SEC source: 0001193125-26-271862 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,621

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.985 to $34.25, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
May 14, 2026 Filed May 18, 2026 20:00 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 153,251 $35.61 $5,457,375.39
Disclosure

SEC source: 0001193125-26-228870 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,184

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.59 to $35.80, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:22 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 19,916 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-098573 · ownership.xml · derivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,748

Underlying: Ordinary Shares · 19,916 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 19,916 vested on March 5, 2026, and 19,916 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029.

F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 19,916 vested on March 5, 2026, and 19,916 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:22 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 19,916 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-098573 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,435

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 53,175 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096513 · ownership.xml · derivative · entry 5

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,175

Underlying: Ordinary Shares · 53,175 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 13,293 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 13,296 vesting on March 4, 2030.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 13,293 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 13,296 vesting on March 4, 2030.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 23,251 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096513 · ownership.xml · derivative · entry 4

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,503

Underlying: Ordinary Shares · 23,251 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 23,251 vested on each of March 4, 2025 and March 4, 2026, 23,251 vesting on March 4, 2027, and 23,253 vesting on March 4, 2028.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 23,251 vested on each of March 4, 2025 and March 4, 2026, 23,251 vesting on March 4, 2027, and 23,253 vesting on March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 33,512 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-096513 · ownership.xml · derivative · entry 3

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 33,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.

F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 23,251 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-096513 · ownership.xml · nonDerivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,519

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2026 Filed Mar 6, 2026 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 33,512 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-096513 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,268

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 141,478 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-093903 · ownership.xml · derivative · entry 4

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 141,478 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

F4 · derivative.expiration_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 49,800 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-093903 · ownership.xml · derivative · entry 3

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,802

Underlying: Ordinary Shares · 49,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024, March 3, 2025 and March 4, 2026, and 49,802 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024, March 3, 2025 and March 4, 2026, and 49,802 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 141,478 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-093903 · ownership.xml · nonDerivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 248,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 49,800 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-093903 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,278

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 26, 2026 Filed Mar 2, 2026 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 345,810 $33.64 $11,634,708.29
Disclosure

SEC source: 0001193125-26-085343 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,478

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.57 to $33.86, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 141,478 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-029337 · ownership.xml · derivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,478

Underlying: Ordinary Shares · 141,478 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.

F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 55,775 $17.08 $952,464.10
Disclosure

SEC source: 0000950170-25-086697 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 403,288

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.055 to $17.12, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 79,664 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-035528 · ownership.xml · derivative · entry 3

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,664

Underlying: Ordinary Shares · 79,664 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 19,916 vesting on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029.

F4 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 19,916 vesting on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 21,390 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-035528 · ownership.xml · derivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 21,390 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022, March 5, 2023, March 5, 2024, and 21,390 vested on March 5, 2025.

F3 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022, March 5, 2023, March 5, 2024, and 21,390 vested on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:19 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 21,390 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-035528 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 459,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 183,169 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034651 · ownership.xml · derivative · entry 6

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 183,169 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025.

F5 · derivative.expiration_date: Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 23,251 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034651 · ownership.xml · derivative · entry 5

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,754

Underlying: Ordinary Shares · 23,251 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 23,251 vested on March 4, 2025, 23,251 vesting on each of March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 23,251 vested on March 4, 2025, 23,251 vesting on each of March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 33,512 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-034651 · ownership.xml · derivative · entry 4

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,512

Underlying: Ordinary Shares · 33,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026.

F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 183,169 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034651 · ownership.xml · nonDerivative · entry 3

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,673

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 23,251 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034651 · ownership.xml · nonDerivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 254,504

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:13 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 33,512 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-034651 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,253

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2025 Filed Mar 4, 2025 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 49,800 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-031946 · ownership.xml · derivative · entry 3

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,602

Underlying: Ordinary Shares · 49,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024 and March 3, 2025, 49,800 vesting on March 3, 2026, and 49,802 vesting on March 3, 2027.

F5 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024 and March 3, 2025, 49,800 vesting on March 3, 2026, and 49,802 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2025 Filed Mar 4, 2025 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 49,800 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-031946 · ownership.xml · nonDerivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 197,741

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F4 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2025 Filed Mar 4, 2025 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 55,750 $16.21 $903,462.20
Disclosure

SEC source: 0000950170-25-031946 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 147,941

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.23, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
January 28, 2025 Filed Jan 30, 2025 21:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 183,169 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-011059 · ownership.xml · derivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183,169

Underlying: Ordinary Shares · 183,169 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025.

F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 06, 2024 Filed Mar 7, 2024 21:27 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 77,550 $13.52 $1,048,119.27
Disclosure

SEC source: 0000950170-24-028015 · ownership.xml · nonDerivative · entry 3

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,691

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:27 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 52,320 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-028015 · ownership.xml · derivative · entry 5

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 52,320 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.

F6 · derivative.expiration_date: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:27 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 21,387 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-028015 · ownership.xml · derivative · entry 4

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,390

Underlying: Ordinary Shares · 21,387 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, and March 5, 2024, and 21,390 vesting on March 5, 2025.

F5 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, and March 5, 2024, and 21,390 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:27 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 21,387 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-028015 · ownership.xml · nonDerivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 281,241

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:27 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 52,320 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-028015 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 259,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 93,005 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025888 · ownership.xml · derivative · entry 5

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,005

Underlying: Ordinary Shares · 93,005 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 23,251 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 23,251 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 33,512 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025888 · ownership.xml · derivative · entry 4

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,534

Underlying: Ordinary Shares · 33,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 33,512 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-025888 · ownership.xml · nonDerivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,534

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 49,800 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025888 · ownership.xml · derivative · entry 3

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,022

Underlying: Ordinary Shares · 49,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 49,800 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 49,802 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 49,800 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 49,802 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 21:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 49,800 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-025888 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,022

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 11:54 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 18,430 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-023530 · ownership.xml · derivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 18,430 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 18,430 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024.

F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 18,430 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 11:54 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 18,430 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-023530 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 12:37 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 6,630 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-015601 · ownership.xml · derivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 6,630 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022, and February 13, 2023, and 6,630 vesting on February 13, 2024.

F3 · derivative.expiration_date: Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022, and February 13, 2023, and 6,630 vesting on February 13, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 12:37 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 6,630 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-015601 · ownership.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,792

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
January 30, 2024 Filed Feb 1, 2024 12:26 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 52,320 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-009614 · ownership.xml · derivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,320

Underlying: Ordinary Shares · 52,320 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024.

F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
August 07, 2023 Filed Aug 9, 2023 20:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 35,125 $9.73 $341,889.19
Disclosure

SEC source: 0001209191-23-045156 · doc4.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,162

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.71 to $9.77, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:10 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 21,387 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016712 · doc4.xml · derivative · entry 5

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,777

Underlying: Ordinary Shares · 21,387 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022 and March 5, 2023, 21,387 vesting on March 5, 2024, and 21,390 vesting on March 5, 2025.

F5 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022 and March 5, 2023, 21,387 vesting on March 5, 2024, and 21,390 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:10 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 21,387 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016712 · doc4.xml · nonDerivative · entry 2

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,287

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:10 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 33,512 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016712 · doc4.xml · derivative · entry 4

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,536

Underlying: Ordinary Shares · 33,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:10 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 33,512 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016712 · doc4.xml · nonDerivative · entry 1

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,900

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2023 Filed Mar 7, 2023 21:10 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 199,202 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016712 · doc4.xml · derivative · entry 3

Kalif Eliyahu Sharon · CIK 0001798443 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,202

Underlying: Ordinary Shares · 199,202 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 49,800 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 49,802 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 49,800 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 49,802 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.